8-K
filed January 16, 2025, 6:59 PM ET
ticker MNTS
CIK 0001781162
other material
confidence high
sentiment neutral
materiality 0.65
Momentus granted Nasdaq listing extension to April 15, 2025; derivative suits settled
Momentus Inc.
- Nasdaq panel extended continued listing to April 15, 2025 to allow compliance with Rule 5550(b) (equity requirement).
- Company regained minimum bid price compliance via reverse stock split on December 12, 2024.
- If equity compliance not achieved by April 15, 2025, common stock will be delisted.
- Court approved settlement of all shareholder derivative litigation; company no longer party to any such suits.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001140361-25-001202
- form_type
- 8-K
- ticker
- MNTS
- cik
- 0001781162
- company_name
- Momentus Inc.
- filed_at
- 2025-01-16T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:04.828280+00:00
- generated_at
- 2026-05-28T00:10:46.410631+00:00
- sec_items
- ["3.01", "7.01", "8.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001140361-25-001202
- json_url
- https://secwatch.observer/filing/0001140361-25-001202.json
- markdown_url
- https://secwatch.observer/filing/0001140361-25-001202.md
- text_url
- https://secwatch.observer/filing/0001140361-25-001202.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1781162/000114036125001202/0001140361-25-001202-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1781162/000114036125001202/ef20041695_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ISPC
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
iSpecimen Inc.
May 13, 2026, 5:00 PM ET
other_material
Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the
Company’s request to continue its listing on The Nasdaq Capital Marke
Comparable filing
minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026
Filing page
SEC filing
AGAE
AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K
Allied Gaming & Entertainment Inc.
May 21, 2026, 9:40 PM ET
other_material
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: other_material
similar materiality
This filing
January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the
Company’s request to continue its listing on The Nasdaq Capital Marke
Comparable filing
May 19, 2026, All In FutureTech Alliance,
Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)
from the Listing Qualifications Department (the “Staff”) of
Filing page
SEC filing
HCWB
Nasdaq panel grants HCW Biologics extension to July 29, 2026 to regain $1 bid price compliance
HCW Biologics Inc.
June 1, 2026, 7:30 AM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the
Company’s request to continue its listing on The Nasdaq Capital Marke
Comparable filing
ng the exception period that may
affect the Company’s compliance with Nasdaq requirements. If the Company regains compliance and satisfies the terms of the exception,
the Panel intends to impose a Discretionary Panel Monitor on the Company for an additional one-year period, pursuant to Listing Rule
5815(d)(4)(A). SIGNATURES Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: June 1, 2026 By: /s/
Hing C. Wong Hing C. Wong, Founder and Chie
Filing page
SEC filing
TNON
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Tenon Medical, Inc.
May 22, 2026, 5:15 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the
Company’s request to continue its listing on The Nasdaq Capital Marke
Comparable filing
May 21, 2026, Tenon Medical, Inc. (the “Company”)
received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying
the Company that it is no longer in compliance with the
Filing page
SEC filing
SNYR
Synergy CHC receives Nasdaq delisting notice for bid price below $1.00
Synergy CHC Corp.
May 18, 2026, 9:01 AM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the
Company’s request to continue its listing on The Nasdaq Capital Marke
Comparable filing
May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of
The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing
Filing page
SEC filing
HUMA
Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply
Humacyte, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the
Company’s request to continue its listing on The Nasdaq Capital Marke
Comparable filing
May 4, 2026, Humacyte, Inc. (the “Company”)
received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification
that, for the 30 consecutive business days ended May 1, 2026, th
Filing page
SEC filing
EMAT
Evolution Metals regains Nasdaq compliance after late 10-Q filing; notice resolved
Evolution Metals & Technologies Corp.
May 26, 2026, 5:28 PM ET
other_material
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: other_material
This filing
January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the
Company’s request to continue its listing on The Nasdaq Capital Marke
Comparable filing
May 21, 2026, Evolution Metals & Technologies
Corp. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The
Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that
Filing page
SEC filing
PMI
Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices
Picard Medical, Inc.
May 21, 2026, 4:15 PM ET
other_material
Items 2.02, 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: other_material
This filing
January 13, 2025, Momentus Inc., a Delaware corporation (the “Company”), received a letter issued by Nasdaq Hearings Panel (the “Panel”) granting the
Company’s request to continue its listing on The Nasdaq Capital Marke
Comparable filing
reviously disclosed, on May
8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together
with the May 15 Notice, the “ Notices ”). In connection with the
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.